文献速递血栓与止血

抗磷脂抗体患者初始静脉或动脉血栓栓塞事件后复发性血栓形成:系统综述与Meta分析

Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta-analysis.
PubMed 文献 · J Thromb Haemost · 2020-07-21

该系统综述与Meta分析检索PubMed、CINAHL、Cochrane和EMBASE,纳入前瞻性试验或队列研究,评估抗磷脂抗体(aPL)合并静脉血栓栓塞(VTE)或动脉血栓栓塞(ATE)患者的2年复发性血栓形成比例。结果显示,VTE患者抗凝治疗时2年复发比例为0.054,未抗凝为0.178;ATE患者抗凝治疗为0.220,抗血小板治疗为0.216。作者认为aPL合并ATE患者可能受益于与VTE患者不同的抗血栓策略,需前瞻性研究确定最佳策略。

要点

  • aPL合并VTE患者抗凝治疗2年复发血栓比例为0.054,未抗凝为0.178。
  • aPL合并ATE患者抗凝治疗2年复发血栓比例为0.220,抗血小板治疗为0.216。
  • 多数研究未区分VTE为诱发性或非诱发性,需前瞻性研究确定最佳抗血栓策略。

核心结论

  • aPL合并ATE患者可能受益于与aPL合并VTE患者不同的抗血栓策略。
  • 需要设计良好的前瞻性队列研究来确定aPL合并TE患者的最佳抗血栓策略。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、CINAHL、Cochrane和EMBASE数据库。
  • 纳入前瞻性试验或队列研究,研究对象为aPL合并ATE或VTE患者。
  • 排除未提供复发率估计、未明确初始事件为ATE或VTE、纳入多次事件患者或纳入少于10例患者的研究。
  • 共10项研究描述VTE患者,2项描述ATE患者,5项描述VTE或ATE患者。
  • 采用随机效应模型估计2年汇总比例。

主要发现

  • VTE患者抗凝治疗时2年复发性TE比例为0.054(95%CI 0.037-0.079)。
  • VTE患者未抗凝治疗时2年复发性TE比例为0.178(95%CI 0.150-0.209)。
  • ATE患者抗凝治疗时2年复发性TE比例为0.220(95%CI 0.149-0.311)。
  • ATE患者抗血小板治疗时2年复发性TE比例为0.216(95%CI 0.177-0.261)。
  • 多数研究未区分VTE为诱发性或非诱发性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 多数研究未区分VTE为诱发性或非诱发性。
  • 需要设计良好的前瞻性队列研究来确定aPL合并TE患者的最佳抗血栓策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with antiphospholipid antibodies (aPL) and thromboembolism (TE) are at risk for recurrent TE. Few studies, however, distinguish patients based on the initial event. OBJECTIVES: We performed a systematic review and meta-analysis to investigate patients with aPL and venous TE (VTE), provoked or unprovoked, and patients with arterial TE (ATE). PATIENTS/METHODS: We conducted searches in PubMed, CINAHL, Cochrane, and EMBASE. Inclusion criteria were prospective trials or cohort studies investigating patients with aPL and ATE or VTE. Excluded studies did not provide estimated recurrence rates, did not specify whether the incident event was ATE or VTE, included patients with multiple events, or included <10 patients. Two-year summary proportions were estimated using a random effects model. RESULTS: Ten studies described patients with VTE, 2 with ATE, and 5 with VTE or ATE. The 2-year proportion for recurrent TE in patients with VTE who were taking anticoagulant therapy was 0.054 (95% confidence interval [CI], 0.037-0.079); the 2-year proportion for patients not taking anticoagulant therapy was 0.178 (95% CI, 0.150-0.209). Most studies did not distinguish whether VTE were provoked or unprovoked. The 2-year proportion for recurrent TE in patients with ATE who were taking anticoagulant therapy was 0.220 (95% CI, 0.149-0.311); the 2-year proportion for patients taking antiplatelet therapy was 0.216 (95% CI, 0.177-0.261). CONCLUSIONS: Patients with aPL and ATE may benefit from a different antithrombotic approach than patients with aPL and VTE. Prospective studies with well-defined cohorts with aPL and TE are necessary to determine optimal antithrombotic strategies.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Ortel TL, Meleth S, Catellier D, et al. Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta-analysis. J Thromb Haemost. 2020. PMID: 32484606. doi:10.1111/jth.14936

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。